Home Cytoskeletal Signaling Integrin antagonist Lifitegrast For research use only.

Lifitegrast

Synonyms: SAR1118,SHP-606

Lifitegrast (SAR1118,SHP-606) is a novel small molecule integrin antagonist that inhibits a specific T cell-mediated inflammatory pathway involved in the pathogenesis of DED.

Lifitegrast Chemical Structure

Lifitegrast Chemical Structure

CAS: 1025967-78-5

Selleck's Lifitegrast has been cited by 3 publications

Purity & Quality Control

Batch: Purity: 99.74%
99.74

Related compound libraries

Choose Selective Integrin Inhibitors

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Jurkat Function assay 1 hr Inhibition of human recombinant ICAM-1 adhesion into human Jurkat cells after 1 hr, IC50=0.00298μM 24900456
HuT-78 Function assay 1 hr Antagonist activity at LFA-1/ICAM-1 in human HuT-78 T-cells assessed as inhibition of cell adhesion after 1 hr by p-nitrophenyl n-acetyl-beta-D-glucosaminide method, IC50=0.009μM 24900456
HuT-78 Function assay 1 hr Antagonist activity at LFA-1/ICAM-1 in human HuT-78 T-cells assessed as inhibition of cell adhesion after 1 hr by p-nitrophenyl n-acetyl-beta-D-glucosaminide method in presence of 10% human serum, IC50=0.074μM 24900456
Click to View More Cell Line Experimental Data

Biological Activity

Description Lifitegrast (SAR1118,SHP-606) is a novel small molecule integrin antagonist that inhibits a specific T cell-mediated inflammatory pathway involved in the pathogenesis of DED.
Targets
Integrin [1]
In vitro
In vitro

Lifitegrast inhibits release of cytokines, interferon d, tumor necrosis factor alpha (TNF-α), and other interleukins (ILs). It is a novel integrin antagonist which prevents LFA-1/ICAM-1 interaction preventing T-cell activation/recruitment and release of inflammatory mediators, thereby decreasing the inflammatory responses in DED[1].
In Vivo
In vivo

In vivo study of lifitegrast as radiolabeled drops in rats demonstrated that it was rapidly distributed in ocular and periocular tissues, cleared by normal tear drainage, and was devoid of systemic side effects. A similar dose tolerability study of lifitegrast in dogs suffering from keratoconjunctivitis sicca proved its efficacy and safety. Lifitegrast is found to be a highly potent drug in various clinical trials as it alleviates both the signs and symptoms of DED, which showed rapid onset of action and good therapeutic efficacy as ophthalmic drops. It protected the corneal surfaces and was well tolerated locally as well as systemically[1].
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05857748 Withdrawn Dry Eye Disease Novartis Pharmaceuticals|Novartis July 31 2023 --
NCT03866629 Completed Dry Eye MDbackline LLC December 20 2018 --
NCT00936520 Terminated Diabetic Macular Edema (DME)|Pars Plana Vitrectomy Johns Hopkins University|SARcode Bioscience August 2009 Phase 1

Chemical lnformation & Solubility

Molecular Weight 615.48 Formula

C29H24Cl2N2O7S
CAS No. 1025967-78-5 SDF Download Lifitegrast SDF
Smiles CS(=O)(=O)C1=CC=CC(=C1)CC(C(=O)O)NC(=O)C2=C(C=C3CN(CCC3=C2Cl)C(=O)C4=CC5=C(C=C4)C=CO5)Cl
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 100 mg/mL ( (162.47 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 20 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Lifitegrast | Lifitegrast ic50 | Lifitegrast price | Lifitegrast cost | Lifitegrast solubility dmso | Lifitegrast purchase | Lifitegrast manufacturer | Lifitegrast research buy | Lifitegrast order | Lifitegrast mouse | Lifitegrast chemical structure | Lifitegrast mw | Lifitegrast molecular weight | Lifitegrast datasheet | Lifitegrast supplier | Lifitegrast in vitro | Lifitegrast cell line | Lifitegrast concentration | Lifitegrast nmr